Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

N4 Pharma Plc (N4P)

Price 0.85p on 19-04-2024 at 16:30:02
Change 0.00p 0%
Buy 0.90p
Sell 0.80p
Buy / Sell N4P Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Buy 1,605.00 at 0.8715p
Day's Volume: 119,308
Last Close: 0.85p
Open: 0.85p
ISIN: GB00BYW8QM32
Day's Range 0.85p - 0.85p
52wk Range: 0.625p - 2.20p
Market Capitalisation: £2m
VWAP: 0.853857p
Shares in Issue: 269m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

Recent Trades History N4 Pharma Plc (N4P)
Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 1,605 0.8715p Ordinary
 14:40:29 - 19-Apr-24
Buy* 59,149 0.8749p Ordinary
 12:21:30 - 19-Apr-24
Buy* 5,555 0.90p SI Trade
 12:20:41 - 19-Apr-24
Sell* 50,000 0.8265p Ordinary
 07:17:38 - 19-Apr-24
Sell* 2,999 0.80p Ordinary
 07:07:16 - 19-Apr-24

Share Price History for N4 Pharma Plc
Time period:
to
Date Open High Low Close Volume

Share News for N4 Pharma Plc

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

18th Apr 2024 12:14

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial. Read More

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

15th Feb 2024 12:06

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says. Read More

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

15th Feb 2024 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More

IN BRIEF: N4 Pharma gets India patent for medical delivery system

19th Jan 2024 09:26

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China. Read More

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

16th Jan 2024 13:26

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London. Read More

FTSE 100 Latest
Value7,895.85
Change18.80

Login to your account

Forgot Password?

Not Registered